faculty_name,faculty_email,publication_type,title,journal,year,doi,url,file_created
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE Trial.,Inflammatory Bowel Diseases,2025,10.1093/ibd/izaf137,https://experts.mcmaster.ca/display/publication3602012,2025-07-27T15:11:22.867022
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparative Predictive Utility of MM-SES-CD and SES-CD for Week 52 Endoscopic Remission in the Ileum and Colon in Crohn's Disease.,Inflammatory Bowel Diseases,2025,10.1093/ibd/izaf124,https://experts.mcmaster.ca/display/publication3596640,2025-07-27T15:11:22.867027
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study.,American Journal of Gastroenterology,2025,10.14309/ajg.0000000000003573,https://experts.mcmaster.ca/display/publication3591258,2025-07-27T15:11:22.867029
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis,Inflammatory Bowel Diseases,2025,10.1093/ibd/izae163,https://experts.mcmaster.ca/display/publication3459078,2025-07-27T15:11:22.867030
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis.",Journal of Crohn's and Colitis,2025,10.1093/ecco-jcc/jjaf041,https://experts.mcmaster.ca/display/publication3554630,2025-07-27T15:11:22.867031
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Novel outcomes in inflammatory bowel disease.,Journal of Crohn's and Colitis,2025,10.1093/ecco-jcc/jjaf040,https://experts.mcmaster.ca/display/publication3554829,2025-07-27T15:11:22.867032
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND Trial.,Journal of Crohn's and Colitis,2025,10.1093/ecco-jcc/jjae171,https://experts.mcmaster.ca/display/publication3486406,2025-07-27T15:11:22.867033
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial.",BMJ Open Gastroenterology,2025,10.1136/bmjgast-2024-001615,https://experts.mcmaster.ca/display/publication3562762,2025-07-27T15:11:22.867034
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel Disease.,Journal of Crohn's and Colitis,2025,10.1093/ecco-jcc/jjae151,https://experts.mcmaster.ca/display/publication3472663,2025-07-27T15:11:22.867035
Neeraj Narula,narulan@mcmaster.ca,journal_articles,A Review of the Modified Multiplier of Simple Endoscopic Score for Crohn's Disease and How to Use It in Clinical Trials and Practice.,American Journal of Gastroenterology,2025,10.14309/ajg.0000000000003373,https://experts.mcmaster.ca/display/publication3545273,2025-07-27T15:11:22.867036
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis.,Gastroenterology,2025,10.1053/j.gastro.2024.10.009,https://experts.mcmaster.ca/display/publication3478275,2025-07-27T15:11:22.867037
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease.,Journal of Crohn's and Colitis,2025,10.1093/ecco-jcc/jjaf006,https://experts.mcmaster.ca/display/publication3525394,2025-07-27T15:11:22.867038
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study).,Crohn's and Colitis 360,2025,10.1093/crocol/otaf013,https://experts.mcmaster.ca/display/publication3558304,2025-07-27T15:11:22.867039
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review,American Journal of Gastroenterology,2025,10.14309/ajg.0000000000002973,https://experts.mcmaster.ca/display/publication3452270,2025-07-27T15:11:22.867040
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Acceptability, feasibility, and impact of the MyGut digital health platform in the monitoring and management of inflammatory bowel disease.",Journal of the Canadian Association of Gastroenterology,2024,10.1093/jcag/gwae029,https://experts.mcmaster.ca/display/publication3504743,2025-07-27T15:11:22.867041
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.,Alimentary Pharmacology and Therapeutics,2024,10.1111/apt.18326,https://experts.mcmaster.ca/display/publication3480443,2025-07-27T15:11:22.867042
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Corrigendum to ""Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials"" volume 72, 102621.",EClinicalMedicine,2024,10.1016/j.eclinm.2024.102980,https://experts.mcmaster.ca/display/publication3494533,2025-07-27T15:11:22.867043
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study.,American Journal of Gastroenterology,2024,10.14309/ajg.0000000000003212,https://experts.mcmaster.ca/display/publication3504742,2025-07-27T15:11:22.867044
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Preliminary Results From a Multicenter, Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's Disease.",American Journal of Gastroenterology,2024,10.14309/ajg.0000000000003196,https://experts.mcmaster.ca/display/publication3488203,2025-07-27T15:11:22.867045
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Perspectives on the sustained engagement with digital health tools: protocol for a qualitative interview study among people living with Inflammatory Bowel Disease or irritable bowel syndrome.,BMJ Open,2024,10.1136/bmjopen-2024-089220,https://experts.mcmaster.ca/display/publication3488435,2025-07-27T15:11:22.867046
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel Disease,Inflammatory Bowel Diseases,2024,10.1093/ibd/izad293,https://experts.mcmaster.ca/display/publication3384673,2025-07-27T15:11:22.867047
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Interventions for Adjunctive Care in Patients With Inflammatory Bowel Disease and Permanent Ileostomy: A Systematic Review.,Crohn's and Colitis 360,2024,10.1093/crocol/otae056,https://experts.mcmaster.ca/display/publication3479873,2025-07-27T15:11:22.867048
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Management of complications in patients with an ileostomy: an umbrella review of systematic reviews for the EndOTrial Consortium.,International Journal of Colorectal Disease,2024,10.1007/s00384-024-04714-8,https://experts.mcmaster.ca/display/publication3472532,2025-07-27T15:11:22.867049
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Defining Endoscopic Remission in Crohn’s Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression,Clinical Gastroenterology and Hepatology,2024,10.1016/j.cgh.2024.02.009,https://experts.mcmaster.ca/display/publication3403343,2025-07-27T15:11:22.867050
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Early Biologic Treatment Decreases Risk of Surgery in Crohn’s Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis,Inflammatory Bowel Diseases,2024,10.1093/ibd/izad149,https://experts.mcmaster.ca/display/publication3276973,2025-07-27T15:11:22.867051
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease,American Journal of Gastroenterology,2024,10.14309/ajg.0000000000002654,https://experts.mcmaster.ca/display/publication3389726,2025-07-27T15:11:22.867052
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn’s Disease: A Systematic Review and Network Meta-Analysis,Clinical Gastroenterology and Hepatology,2024,10.1016/j.cgh.2023.12.023,https://experts.mcmaster.ca/display/publication3386633,2025-07-27T15:11:22.867053
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY,European Journal of Gastroenterology and Hepatology,2024,10.1097/meg.0000000000002759,https://experts.mcmaster.ca/display/publication3409104,2025-07-27T15:11:22.867054
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials,EClinicalMedicine,2024,10.1016/j.eclinm.2024.102621,https://experts.mcmaster.ca/display/publication3427026,2025-07-27T15:11:22.867055
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Resolution of rectal bleeding by day 7 in acute severe ulcerative colitis is prognostic for post-discharge corticosteroid free clinical remission and endoscopic improvement,American Journal of Gastroenterology,2024,10.14309/ajg.0000000000002860,https://experts.mcmaster.ca/display/publication3431652,2025-07-27T15:11:22.867056
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's disease,Digestive and Liver Disease,2024,10.1016/j.dld.2024.04.017,https://experts.mcmaster.ca/display/publication3437413,2025-07-27T15:11:22.867057
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Pharmacological Therapies for the Management of Fistulizing Crohn’s Disease: A Systematic Review and Meta-Analysis,Journal of Crohn's and Colitis,2024,10.1093/ecco-jcc/jjad185,https://experts.mcmaster.ca/display/publication3307352,2025-07-27T15:11:22.867058
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Endoscopic and Histological Placebo Rates in Crohn’s Disease Clinical Trials: A Systematic Review and Meta-analysis,Inflammatory Bowel Diseases,2024,10.1093/ibd/izad052,https://experts.mcmaster.ca/display/publication3010261,2025-07-27T15:11:22.867059
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases,Gastroenterology,2024,10.1053/j.gastro.2023.10.033,https://experts.mcmaster.ca/display/publication3309164,2025-07-27T15:11:22.867060
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index,Inflammatory Bowel Diseases,2024,10.1093/ibd/izad074,https://experts.mcmaster.ca/display/publication3190786,2025-07-27T15:11:22.867061
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy,Inflammatory Bowel Diseases,2024,10.1093/ibd/izad077,https://experts.mcmaster.ca/display/publication3242731,2025-07-27T15:11:22.867062
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis,Inflammatory Bowel Diseases,2024,10.1093/ibd/izad013,https://experts.mcmaster.ca/display/publication2922723,2025-07-27T15:11:22.867063
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Editorial: Moving towards prognostic endoscopic scoring in IBD,Alimentary Pharmacology and Therapeutics,2024,10.1111/apt.17787,https://experts.mcmaster.ca/display/publication3324567,2025-07-27T15:11:22.867064
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Patient Experience with the SensoReady® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn´s Disease,Patient Preference and Adherence,2024,10.2147/ppa.s455791,https://experts.mcmaster.ca/display/publication3441719,2025-07-27T15:11:22.867065
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study,Digestive and Liver Disease,2024,10.1016/j.dld.2023.08.042,https://experts.mcmaster.ca/display/publication3294107,2025-07-27T15:11:22.867066
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders,Clinical Gastroenterology and Hepatology,2023,10.1016/j.cgh.2023.06.011,https://experts.mcmaster.ca/display/publication3258356,2025-07-27T15:11:22.867067
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis,Journal of Crohn's and Colitis,2023,10.1093/ecco-jcc/jjad100,https://experts.mcmaster.ca/display/publication3251431,2025-07-27T15:11:22.867068
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn’s Disease,Journal of Clinical Gastroenterology,2023,10.1097/mcg.0000000000001774,https://experts.mcmaster.ca/display/publication3242733,2025-07-27T15:11:22.867069
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis,European Journal of Gastroenterology and Hepatology,2023,10.1097/meg.0000000000002623,https://experts.mcmaster.ca/display/publication3281920,2025-07-27T15:11:22.867070
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic review with meta‐analysis: Medical therapies for treatment of ulcerative proctitis,Alimentary Pharmacology and Therapeutics,2023,10.1111/apt.17666,https://experts.mcmaster.ca/display/publication3281919,2025-07-27T15:11:22.867071
Neeraj Narula,narulan@mcmaster.ca,journal_articles,The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review,Digestive and Liver Disease,2023,10.1016/j.dld.2023.05.021,https://experts.mcmaster.ca/display/publication3253726,2025-07-27T15:11:22.867072
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study",Clinical Gastroenterology and Hepatology,2023,10.1016/j.cgh.2022.11.037,https://experts.mcmaster.ca/display/publication2951618,2025-07-27T15:11:22.867073
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn’s Disease: Systematic Review and Meta-Analysis,Digestive Diseases and Sciences,2023,10.1007/s10620-023-08014-z,https://experts.mcmaster.ca/display/publication3255545,2025-07-27T15:11:22.867074
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis,Clinical Gastroenterology and Hepatology,2023,10.1016/j.cgh.2023.01.012,https://experts.mcmaster.ca/display/publication3068329,2025-07-27T15:11:22.867074
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease,Inflammatory Bowel Diseases,2023,10.1093/ibd/izac231,https://experts.mcmaster.ca/display/publication2579479,2025-07-27T15:11:22.867075
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study,Saudi Pharmaceutical Journal,2023,10.1016/j.jsps.2023.101736,https://experts.mcmaster.ca/display/publication3284392,2025-07-27T15:11:22.867076
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis,Inflammatory Bowel Diseases,2023,10.1093/ibd/izac210,https://experts.mcmaster.ca/display/publication2435761,2025-07-27T15:11:22.867077
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY study,Journal of Crohn's and Colitis,2023,10.1093/ecco-jcc/jjad033,https://experts.mcmaster.ca/display/publication2864764,2025-07-27T15:11:22.867078
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn’s Disease,Inflammatory Bowel Diseases,2023,10.1093/ibd/izac168,https://experts.mcmaster.ca/display/publication2423411,2025-07-27T15:11:22.867080
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions,Journal of Crohn's and Colitis,2023,10.1093/ecco-jcc/jjad020,https://experts.mcmaster.ca/display/publication2864765,2025-07-27T15:11:22.867081
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Patients With Crohn's Disease and Permanent Ileostomy Are Universally Excluded From Clinical Trials: A Systematic Review,American Journal of Gastroenterology,2023,10.14309/ajg.0000000000002215,https://experts.mcmaster.ca/display/publication2835522,2025-07-27T15:11:22.867082
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study,Digestive Diseases and Sciences,2023,10.1007/s10620-023-07956-8,https://experts.mcmaster.ca/display/publication3127668,2025-07-27T15:11:22.867082
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease,Inflammatory Bowel Diseases,2023,10.1093/ibd/izac157,https://experts.mcmaster.ca/display/publication2421127,2025-07-27T15:11:22.867083
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission,Digestive Diseases and Sciences,2023,10.1007/s10620-023-07825-4,https://experts.mcmaster.ca/display/publication2746201,2025-07-27T15:11:22.867084
Neeraj Narula,narulan@mcmaster.ca,journal_articles,REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis,American Journal of Gastroenterology,2023,10.14309/ajg.0000000000002129,https://experts.mcmaster.ca/display/publication3239421,2025-07-27T15:11:22.867086
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis,Journal of Crohn's and Colitis,2023,10.1093/ecco-jcc/jjac160,https://experts.mcmaster.ca/display/publication2553186,2025-07-27T15:11:22.867087
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Beyond the White Pill: Advocating for Racial Diversity in IBD Trials,Journal of Crohn's and Colitis,2023,10.1093/ecco-jcc/jjac134,https://experts.mcmaster.ca/display/publication2429670,2025-07-27T15:11:22.867087
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies,Journal of Crohn's and Colitis,2023,10.1093/ecco-jcc/jjac150,https://experts.mcmaster.ca/display/publication2435770,2025-07-27T15:11:22.867088
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Correspondence on “PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system” by Guiet al,Gut,2023,10.1136/gutjnl-2022-327661,https://experts.mcmaster.ca/display/publication2232253,2025-07-27T15:11:22.867089
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Predictors of Placebo Induction Response and Remission in Ulcerative Colitis,Clinical Gastroenterology and Hepatology,2023,10.1016/j.cgh.2022.08.015,https://experts.mcmaster.ca/display/publication2473035,2025-07-27T15:11:22.867090
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Time to Endorse A Sensitive Method for Scoring Endoscopic Activity of Ulcerative Colitis in Clinical Research,Journal of Crohn's and Colitis,2023,10.1093/ecco-jcc/jjac120,https://experts.mcmaster.ca/display/publication2429671,2025-07-27T15:11:22.867092
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Clinical remission in paired phase two and three studies in inflammatory bowel disease: a systematic review with meta-analysis,European Journal of Gastroenterology and Hepatology,2023,10.1097/meg.0000000000002490,https://experts.mcmaster.ca/display/publication2777572,2025-07-27T15:11:22.867093
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials",Inflammatory Bowel Diseases,2023,10.1093/ibd/izac128,https://experts.mcmaster.ca/display/publication2315339,2025-07-27T15:11:22.867097
Neeraj Narula,narulan@mcmaster.ca,journal_articles,The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium,American Journal of Gastroenterology,2023,10.14309/ajg.0000000000002047,https://experts.mcmaster.ca/display/publication2835262,2025-07-27T15:11:22.867098
Neeraj Narula,narulan@mcmaster.ca,journal_articles,The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis,Intestinal Research,2023,10.5217/ir.2022.00006,https://experts.mcmaster.ca/display/publication3068328,2025-07-27T15:11:22.867099
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Placebo Rates in Randomized Controlled Trials of Proctitis Therapy: A Systematic Review and Meta-Analysis Placebo Response in Proctitis,Journal of Crohn's and Colitis,2023,10.1093/ecco-jcc/jjac109,https://experts.mcmaster.ca/display/publication2429655,2025-07-27T15:11:22.867100
Neeraj Narula,narulan@mcmaster.ca,journal_articles,End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis,Scandinavian Journal of Gastroenterology,2023,10.1080/00365521.2022.2105169,https://experts.mcmaster.ca/display/publication2421125,2025-07-27T15:11:22.867101
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study,American Journal of Gastroenterology,2023,10.14309/ajg.0000000000001987,https://experts.mcmaster.ca/display/publication2429672,2025-07-27T15:11:22.867102
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Pilot study of an elimination diet in adults with mild to moderate Crohn’s disease,European Journal of Gastroenterology and Hepatology,2022,10.1097/meg.0000000000002438,https://experts.mcmaster.ca/display/publication2472497,2025-07-27T15:11:22.867103
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series,Digestive Diseases and Sciences,2022,10.1007/s10620-022-07439-2,https://experts.mcmaster.ca/display/publication2173066,2025-07-27T15:11:22.867104
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab,Inflammatory Bowel Diseases,2022,10.1093/ibd/izab310,https://experts.mcmaster.ca/display/publication2157222,2025-07-27T15:11:22.867105
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Case Report: Managing Postoperative Crohn's Disease.,Gastroenterology and Hepatology,2022,,https://experts.mcmaster.ca/display/publication2445203,2025-07-27T15:11:22.867106
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease,Journal of Clinical Gastroenterology,2022,10.1097/mcg.0000000000001636,https://experts.mcmaster.ca/display/publication2152104,2025-07-27T15:11:22.867107
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Categorising Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD [MM-SES-CD],Journal of Crohn's and Colitis,2022,10.1093/ecco-jcc/jjac018,https://experts.mcmaster.ca/display/publication2167612,2025-07-27T15:11:22.867108
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease,Clinical Gastroenterology and Hepatology,2022,10.1016/j.cgh.2021.04.006,https://experts.mcmaster.ca/display/publication1966171,2025-07-27T15:11:22.867109
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis,Clinical Gastroenterology and Hepatology,2022,10.1016/j.cgh.2021.07.038,https://experts.mcmaster.ca/display/publication2152404,2025-07-27T15:11:22.867110
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD),Gut,2022,10.1136/gutjnl-2020-323799,https://experts.mcmaster.ca/display/publication1964783,2025-07-27T15:11:22.867111
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Reply,Clinical Gastroenterology and Hepatology,2022,10.1016/j.cgh.2021.08.024,https://experts.mcmaster.ca/display/publication2189441,2025-07-27T15:11:22.867112
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy,Journal of Gastroenterology and Hepatology,2022,10.1111/jgh.15806,https://experts.mcmaster.ca/display/publication2176323,2025-07-27T15:11:22.867113
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s Disease,Journal of Crohn's and Colitis,2022,10.1093/ecco-jcc/jjab183,https://experts.mcmaster.ca/display/publication2157223,2025-07-27T15:11:22.867114
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Clinical Decision Support Tool for Infliximab in Crohn’s Disease,Clinical Gastroenterology and Hepatology,2022,10.1016/j.cgh.2021.06.037,https://experts.mcmaster.ca/display/publication1986949,2025-07-27T15:11:22.867115
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis,Clinical Gastroenterology and Hepatology,2022,10.1016/j.cgh.2021.07.005,https://experts.mcmaster.ca/display/publication1986950,2025-07-27T15:11:22.867116
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis,Digestive Diseases and Sciences,2022,10.1007/s10620-021-07151-7,https://experts.mcmaster.ca/display/publication2048244,2025-07-27T15:11:22.867117
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Reply,Clinical Gastroenterology and Hepatology,2022,10.1016/j.cgh.2021.05.051,https://experts.mcmaster.ca/display/publication1970900,2025-07-27T15:11:22.867118
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease,Alimentary Pharmacology and Therapeutics,2022,10.1111/apt.16805,https://experts.mcmaster.ca/display/publication2167611,2025-07-27T15:11:22.867119
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis,Scandinavian Journal of Gastroenterology,2022,10.1080/00365521.2021.2015801,https://experts.mcmaster.ca/display/publication2157229,2025-07-27T15:11:22.867120
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Editorial: is it not justPROs, but the most important individualPRO, that really matters in Crohn’s disease? Authors’ reply",Alimentary Pharmacology and Therapeutics,2022,10.1111/apt.16866,https://experts.mcmaster.ca/display/publication2182415,2025-07-27T15:11:22.867121
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis,BMJ Open Gastroenterology,2022,10.1136/bmjgast-2021-000853,https://experts.mcmaster.ca/display/publication2173067,2025-07-27T15:11:22.867122
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis,Gastroenterology,2021,10.1053/j.gastro.2021.07.043,https://experts.mcmaster.ca/display/publication2137006,2025-07-27T15:11:22.867123
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis,Journal of Crohn's and Colitis,2021,10.1093/ecco-jcc/jjab045,https://experts.mcmaster.ca/display/publication1961799,2025-07-27T15:11:22.867124
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Declining Use of Corticosteroids for Crohn’s Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial,Journal of the Canadian Association of Gastroenterology,2021,10.1093/jcag/gwaa037,https://experts.mcmaster.ca/display/publication2132392,2025-07-27T15:11:22.867125
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Comparative effectiveness of higher adalimumab maintenance therapyversusstandard dose in anti‐tumor necrosis factor experienced Crohn's disease patients: A propensity‐score matched cohort analysis,Journal of Gastroenterology and Hepatology,2021,10.1111/jgh.15551,https://experts.mcmaster.ca/display/publication1970011,2025-07-27T15:11:22.867126
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study,Gastroenterology,2021,10.1053/j.gastro.2021.06.007,https://experts.mcmaster.ca/display/publication1981841,2025-07-27T15:11:22.867127
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn’s disease patients,European Journal of Gastroenterology and Hepatology,2021,10.1097/meg.0000000000002250,https://experts.mcmaster.ca/display/publication2124125,2025-07-27T15:11:22.867128
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic review and meta‐analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease,Journal of Gastroenterology and Hepatology,2021,10.1111/jgh.15574,https://experts.mcmaster.ca/display/publication1981840,2025-07-27T15:11:22.867129
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis,Journal of Crohn's and Colitis,2021,10.1093/ecco-jcc/jjab030,https://experts.mcmaster.ca/display/publication1959560,2025-07-27T15:11:22.867130
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Intake of artificial sweeteners among adults is associated with reduced odds of gastrointestinal luminal cancers: a meta-analysis of cohort and case-control studies,Progress in Food and Nutrition Science,2021,10.1016/j.nutres.2021.07.007,https://experts.mcmaster.ca/display/publication2124126,2025-07-27T15:11:22.867131
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews,Inflammatory Bowel Diseases,2021,10.1093/ibd/izaa350,https://experts.mcmaster.ca/display/publication1956936,2025-07-27T15:11:22.867132
Neeraj Narula,narulan@mcmaster.ca,journal_articles,A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease,American Journal of Gastroenterology,2021,10.14309/ajg.0000000000001263,https://experts.mcmaster.ca/display/publication2135020,2025-07-27T15:11:22.867133
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study,The BMJ,2021,10.1136/bmj.n1554,https://experts.mcmaster.ca/display/publication2010132,2025-07-27T15:11:22.867134
Neeraj Narula,narulan@mcmaster.ca,journal_articles,End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn’s Disease,Journal of Crohn's and Colitis,2021,10.1093/ecco-jcc/jjaa242,https://experts.mcmaster.ca/display/publication1939302,2025-07-27T15:11:22.867135
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses,EClinicalMedicine,2021,10.1016/j.eclinm.2021.100884,https://experts.mcmaster.ca/display/publication1971167,2025-07-27T15:11:22.867135
Neeraj Narula,narulan@mcmaster.ca,journal_articles,The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: Apost hocanalysis of the UNITI studies,United European Gastroenterology Journal,2021,10.1002/ueg2.12094,https://experts.mcmaster.ca/display/publication1978971,2025-07-27T15:11:22.867136
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial,Inflammatory Bowel Diseases,2021,10.1093/ibd/izaa214,https://experts.mcmaster.ca/display/publication1923186,2025-07-27T15:11:22.867137
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Editorial: methotrexate in patients with Crohn's disease refractory to anti‐TNF therapy—moving backwards yet forward?,Alimentary Pharmacology and Therapeutics,2021,10.1111/apt.16327,https://experts.mcmaster.ca/display/publication1964782,2025-07-27T15:11:22.867139
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn’s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials,Journal of Crohn's and Colitis,2021,10.1093/ecco-jcc/jjaa189,https://experts.mcmaster.ca/display/publication1926543,2025-07-27T15:11:22.867140
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn’s Recurrence: Systematic Review and Meta-analysis",Clinical Gastroenterology and Hepatology,2021,10.1016/j.cgh.2020.08.014,https://experts.mcmaster.ca/display/publication1923187,2025-07-27T15:11:22.867141
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn’s Disease: A Systematic Review and Pooled Meta-analysis,Clinical Gastroenterology and Hepatology,2021,10.1016/j.cgh.2020.06.036,https://experts.mcmaster.ca/display/publication1916862,2025-07-27T15:11:22.867142
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Impact of Digital Health Monitoring in the Management of Inflammatory Bowel Disease,Journal of Medical Systems,2021,10.1007/s10916-021-01706-x,https://experts.mcmaster.ca/display/publication1956937,2025-07-27T15:11:22.867143
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Mode of Delivery Does Not Affect the Risk of Inflammatory Bowel Disease,Digestive Diseases and Sciences,2021,10.1007/s10620-020-06204-7,https://experts.mcmaster.ca/display/publication1701189,2025-07-27T15:11:22.867144
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis,Inflammatory Bowel Diseases,2020,10.1093/ibd/izaa020,https://experts.mcmaster.ca/display/publication1691591,2025-07-27T15:11:22.867144
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease,Cochrane Database of Systematic Reviews,2020,10.1002/14651858.cd013256.pub2,https://experts.mcmaster.ca/display/publication1935984,2025-07-27T15:11:22.867145
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial,American Journal of Gastroenterology,2020,10.14309/ajg.0000000000000617,https://experts.mcmaster.ca/display/publication1920338,2025-07-27T15:11:22.867146
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease,Scandinavian Journal of Gastroenterology,2020,10.1080/00365521.2020.1780470,https://experts.mcmaster.ca/display/publication1915916,2025-07-27T15:11:22.867147
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors,American Journal of Gastroenterology,2020,10.14309/ajg.0000000000000596,https://experts.mcmaster.ca/display/publication1893561,2025-07-27T15:11:22.867148
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Letter: mesalazine—a safe drug with rare serious adverse events? Authors’ reply,Alimentary Pharmacology and Therapeutics,2020,10.1111/apt.15748,https://experts.mcmaster.ca/display/publication1905884,2025-07-27T15:11:22.867149
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness,Journal of the Canadian Association of Gastroenterology,2020,10.1093/jcag/gwy065,https://experts.mcmaster.ca/display/publication1743441,2025-07-27T15:11:22.867150
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Prevalence of endoscopic improvement and remission according to patient‐reported outcomes in ulcerative colitis,Alimentary Pharmacology and Therapeutics,2020,10.1111/apt.15577,https://experts.mcmaster.ca/display/publication1680386,2025-07-27T15:11:22.867151
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Is Blood Urea Concentration an Independent Predictor of Positive Endoscopic Findings in Presumed Upper Gastrointestinal Bleeding?,Digestive Diseases,2020,10.1159/000501549,https://experts.mcmaster.ca/display/publication1654095,2025-07-27T15:11:22.867152
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis,PLoS ONE,2020,10.1371/journal.pone.0233781,https://experts.mcmaster.ca/display/publication1914162,2025-07-27T15:11:22.867153
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis—A Systematic Review and Meta-analysis,Clinical Gastroenterology and Hepatology,2019,10.1016/j.cgh.2019.01.013,https://experts.mcmaster.ca/display/publication1620999,2025-07-27T15:11:22.867154
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Response to Letter by Moulton et al.,Inflammatory Bowel Diseases,2019,10.1093/ibd/izz035,https://experts.mcmaster.ca/display/publication1631396,2025-07-27T15:11:22.867155
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic review with meta‐analysis: association betweenHelicobacter pyloriCagA seropositivity and odds of inflammatory bowel disease,Alimentary Pharmacology and Therapeutics,2019,10.1111/apt.15306,https://experts.mcmaster.ca/display/publication1644604,2025-07-27T15:11:22.867156
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease,Inflammatory Bowel Diseases,2019,10.1093/ibd/izy385,https://experts.mcmaster.ca/display/publication1618926,2025-07-27T15:11:22.867157
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease,Scandinavian Journal of Gastroenterology,2019,10.1080/00365521.2019.1621367,https://experts.mcmaster.ca/display/publication1643196,2025-07-27T15:11:22.867158
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium,American Journal of Gastroenterology,2019,10.1038/s41395-018-0401-4,https://experts.mcmaster.ca/display/publication1607289,2025-07-27T15:11:22.867159
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease,Cochrane Database of Systematic Reviews,2019,10.1002/14651858.cd013256,https://experts.mcmaster.ca/display/publication1747429,2025-07-27T15:11:22.867160
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis,Clinical Gastroenterology and Hepatology,2019,10.1016/j.cgh.2018.06.015,https://experts.mcmaster.ca/display/publication1553059,2025-07-27T15:11:22.867161
Neeraj Narula,narulan@mcmaster.ca,journal_articles,"Impact of Adalimumab Patient Support Program’s Care Coach Calls on Clinical
          Outcomes in Patients with Crohn’s Disease in Canada: An Observational Retrospective Cohort
          Study",Journal of the Canadian Association of Gastroenterology,2018,10.1093/jcag/gwy059,https://experts.mcmaster.ca/display/publication1652657,2025-07-27T15:11:22.867162
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease,Gastroenterology,2018,10.1053/j.gastro.2018.05.039,https://experts.mcmaster.ca/display/publication1543144,2025-07-27T15:11:22.867163
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium,American Journal of Gastroenterology,2018,10.1038/s41395-018-0162-0,https://experts.mcmaster.ca/display/publication1561805,2025-07-27T15:11:22.867164
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Safety of Propofol versus Nonpropofol-Based Sedation in Children Undergoing Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis,Gastroenterology Research and Practice,2018,10.1155/2018/6501215,https://experts.mcmaster.ca/display/publication1590343,2025-07-27T15:11:22.867165
Neeraj Narula,narulan@mcmaster.ca,journal_articles,The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease,Inflammatory Bowel Diseases,2018,10.1093/ibd/izy195,https://experts.mcmaster.ca/display/publication1543143,2025-07-27T15:11:22.867166
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic review: safety of mesalazine in ulcerative colitis,Alimentary Pharmacology and Therapeutics,2018,10.1111/apt.14688,https://experts.mcmaster.ca/display/publication1524689,2025-07-27T15:11:22.867167
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Role of endoscopy in inflammatory bowel disease,Gastroenterology Report,2018,10.1093/gastro/goy006,https://experts.mcmaster.ca/display/publication1543142,2025-07-27T15:11:22.867168
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease,Journal of Crohn's and Colitis,2018,10.1093/ecco-jcc/jjy022,https://experts.mcmaster.ca/display/publication1524692,2025-07-27T15:11:22.867169
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Enteral nutritional therapy for induction of remission in Crohn's disease,Cochrane Database of Systematic Reviews,2018,10.1002/14651858.cd000542.pub3,https://experts.mcmaster.ca/display/publication1514128,2025-07-27T15:11:22.867170
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic Review and Meta-analysis,Inflammatory Bowel Diseases,2017,10.1097/mib.0000000000001228,https://experts.mcmaster.ca/display/publication1458956,2025-07-27T15:11:22.867171
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis.,Inflammatory Bowel Diseases,2017,10.1097/MIB.0000000000001228,https://experts.mcmaster.ca/display/publication1458955,2025-07-27T15:11:22.867172
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic review with meta‐analysis: proximal disease extension in limited ulcerative colitis,Alimentary Pharmacology and Therapeutics,2017,10.1111/apt.14063,https://experts.mcmaster.ca/display/publication816946,2025-07-27T15:11:22.867173
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Trends in Narcotic and Corticosteroid Prescriptions in Patients with Inflammatory Bowel Disease in the United States Ambulatory Care Setting from 2003 to 2011,Inflammatory Bowel Diseases,2017,10.1097/mib.0000000000001084,https://experts.mcmaster.ca/display/publication816948,2025-07-27T15:11:22.867178
Neeraj Narula,narulan@mcmaster.ca,journal_articles,The morbidity and mortality of hepaticojejunostomies for complex bile duct injuries: a multi-institutional analysis of risk factors and outcomes using NSQIP,HPB,2017,10.1016/j.hpb.2016.12.004,https://experts.mcmaster.ca/display/publication816961,2025-07-27T15:11:22.867179
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Review article: dose optimisation of infliximab for acute severe ulcerative colitis,Alimentary Pharmacology and Therapeutics,2017,10.1111/apt.13913,https://experts.mcmaster.ca/display/publication816967,2025-07-27T15:11:22.867180
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Preventive care for a 35-year-old woman with inflammatory bowel disease,CANADIAN MEDICAL ASSOCIATION JOURNAL,2017,10.1503/cmaj.160640,https://experts.mcmaster.ca/display/publication816957,2025-07-27T15:11:22.867181
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn’s Disease in Remission: A Pilot Randomized Double-Blind Controlled Study,Digestive Diseases and Sciences,2017,10.1007/s10620-016-4396-7,https://experts.mcmaster.ca/display/publication485208,2025-07-27T15:11:22.867182
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases,Gastroenterology,2017,10.1053/j.gastro.2016.09.046,https://experts.mcmaster.ca/display/publication816986,2025-07-27T15:11:22.867183
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease – should one consider disease location? Authors’ reply,Alimentary Pharmacology and Therapeutics,2016,10.1111/apt.13768,https://experts.mcmaster.ca/display/publication436492,2025-07-27T15:11:22.867184
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis,Clinical Gastroenterology and Hepatology,2016,10.1016/j.cgh.2016.01.015,https://experts.mcmaster.ca/display/publication817000,2025-07-27T15:11:22.867185
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Reply,Clinical Gastroenterology and Hepatology,2016,10.1016/j.cgh.2016.04.002,https://experts.mcmaster.ca/display/publication816996,2025-07-27T15:11:22.867186
Neeraj Narula,narulan@mcmaster.ca,journal_articles,The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium,American Journal of Gastroenterology,2016,10.1038/ajg.2016.236,https://experts.mcmaster.ca/display/publication799726,2025-07-27T15:11:22.867186
Neeraj Narula,narulan@mcmaster.ca,journal_articles,The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐TNF‐α naïve Crohn's disease,Alimentary Pharmacology and Therapeutics,2016,10.1111/apt.13671,https://experts.mcmaster.ca/display/publication436500,2025-07-27T15:11:22.867190
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Letter: mucosal healing is associated with improved long‐term outcomes in Crohn's disease – authors' reply,Alimentary Pharmacology and Therapeutics,2016,10.1111/apt.13637,https://experts.mcmaster.ca/display/publication816992,2025-07-27T15:11:22.867191
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies),Inflammatory Bowel Diseases,2016,10.1097/mib.0000000000000703,https://experts.mcmaster.ca/display/publication816998,2025-07-27T15:11:22.867192
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids,American Journal of Gastroenterology,2016,10.1038/ajg.2016.7,https://experts.mcmaster.ca/display/publication436508,2025-07-27T15:11:22.867193
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease,Alimentary Pharmacology and Therapeutics,2016,10.1111/apt.13475,https://experts.mcmaster.ca/display/publication817003,2025-07-27T15:11:22.867194
Neeraj Narula,narulan@mcmaster.ca,journal_articles,When to perform gastroscopy in the PSC patient,Annals of Hepatology,2016,10.5604/16652681.1184294,https://experts.mcmaster.ca/display/publication817002,2025-07-27T15:11:22.867195
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Systematic Review,Inflammatory Bowel Diseases,2015,10.1097/mib.0000000000000350,https://experts.mcmaster.ca/display/publication436558,2025-07-27T15:11:22.867196
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Management of Severe Ulcerative Colitis,Current Treatment Options in Gastroenterology,2015,10.1007/s11938-014-0036-5,https://experts.mcmaster.ca/display/publication817019,2025-07-27T15:11:22.867197
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease,Inflammatory Bowel Diseases,2014,10.1097/mib.0000000000000092,https://experts.mcmaster.ca/display/publication485256,2025-07-27T15:11:22.867198
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Combination Therapy With Methotrexate in Inflammatory Bowel Disease: Time to COMMIT?,Gastroenterology,2014,10.1053/j.gastro.2014.01.040,https://experts.mcmaster.ca/display/publication817040,2025-07-27T15:11:22.867199
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Fecal Occult Blood Testing as a Diagnostic Test in Symptomatic Patients is not Useful: A Retrospective Chart Review,Canadian Journal of Gastroenterology and Hepatology,2014,10.1155/2014/189652,https://experts.mcmaster.ca/display/publication485246,2025-07-27T15:11:22.867200
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests?,Journal of Gastroenterology and Hepatology,2013,10.1111/jgh.12201,https://experts.mcmaster.ca/display/publication485339,2025-07-27T15:11:22.867201
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Meta‐analysis: peri‐operative anti‐TNFα treatment and post‐operative complications in patients with inflammatory bowel disease,Alimentary Pharmacology and Therapeutics,2013,10.1111/apt.12313,https://experts.mcmaster.ca/display/publication485365,2025-07-27T15:11:22.867202
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Meta‐analysis: colonoscopic post‐polypectomy bleeding in patients on continued clopidogrel therapy,Alimentary Pharmacology and Therapeutics,2013,10.1111/apt.12292,https://experts.mcmaster.ca/display/publication485357,2025-07-27T15:11:22.867203
Neeraj Narula,narulan@mcmaster.ca,journal_articles,An evaluation of the ‘5 Minute Medicine’ video podcast series compared to conventional medical resources for the internal medicine clerkship,Medical Teacher,2012,10.3109/0142159x.2012.689446,https://experts.mcmaster.ca/display/publication811997,2025-07-27T15:11:22.867204
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?,American Journal of Medicine,2012,10.1016/j.amjmed.2012.03.015,https://experts.mcmaster.ca/display/publication485371,2025-07-27T15:11:22.867205
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Management of inflammatory bowel disease with vitamin D: Beyond bone health,Journal of Crohn's and Colitis,2012,10.1016/j.crohns.2011.10.015,https://experts.mcmaster.ca/display/publication485367,2025-07-27T15:11:22.867206
Neeraj Narula,narulan@mcmaster.ca,journal_articles,An Audit of Influenza Vaccination Status in Adults with Inflammatory Bowel Disease,Canadian Journal of Gastroenterology and Hepatology,2012,10.1155/2012/158362,https://experts.mcmaster.ca/display/publication485335,2025-07-27T15:11:22.867206
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Should Albumin Be Used in All Patients with Spontaneous Bacterial Peritonitis?,Canadian Journal of Gastroenterology and Hepatology,2011,10.1155/2011/586702,https://experts.mcmaster.ca/display/publication485433,2025-07-27T15:11:22.867208
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Role of probiotics in management of diverticular disease,Journal of Gastroenterology and Hepatology,2010,10.1111/j.1440-1746.2010.06444.x,https://experts.mcmaster.ca/display/publication485413,2025-07-27T15:11:22.867209
Neeraj Narula,narulan@mcmaster.ca,journal_articles,IgG4-Related Sclerosing Disease: A Novel Mimic of Inflammatory Bowel Disease,Digestive Diseases and Sciences,2010,10.1007/s10620-010-1287-1,https://experts.mcmaster.ca/display/publication485417,2025-07-27T15:11:22.867210
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Should My Patient with Inflammatory Bowel Disease on Immunosuppressive Therapy be Vaccinated against Influenza Virus?,Canadian Journal of Gastroenterology and Hepatology,2010,10.1155/2010/375878,https://experts.mcmaster.ca/display/publication485472,2025-07-27T15:11:22.867210
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?,Canadian Journal of Gastroenterology and Hepatology,2009,10.1155/2009/431349,https://experts.mcmaster.ca/display/publication817129,2025-07-27T15:11:22.867211
Neeraj Narula,narulan@mcmaster.ca,journal_articles,Exercise and Inflammatory Bowel Disease,Canadian Journal of Gastroenterology and Hepatology,2008,10.1155/2008/785953,https://experts.mcmaster.ca/display/publication817141,2025-07-27T15:11:22.867212
Neeraj Narula,narulan@mcmaster.ca,conferences,Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis,Journal of Crohn's and Colitis,2024,10.1093/ecco-jcc/jjae092,https://experts.mcmaster.ca/display/publication3414760,2025-07-27T15:11:22.867214
Neeraj Narula,narulan@mcmaster.ca,conferences,Tofacitinib for hospitalized acute severe Ulcerative Colitis - the TRIUMPH study,Crohn's and Colitis 360,2024,10.1093/crocol/otaf013,https://experts.mcmaster.ca/display/publication3412884,2025-07-27T15:11:22.867215
Neeraj Narula,narulan@mcmaster.ca,conferences,"The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn’s Disease",Inflammatory Bowel Diseases,2023,10.1093/ibd/izac130,https://experts.mcmaster.ca/display/publication2187540,2025-07-27T15:11:22.867216
Neeraj Narula,narulan@mcmaster.ca,conferences,Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease,American Journal of Gastroenterology,2022,10.14309/ajg.0000000000001795,https://experts.mcmaster.ca/display/publication2187537,2025-07-27T15:11:22.867217
Neeraj Narula,narulan@mcmaster.ca,conferences,Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission,Alimentary Pharmacology and Therapeutics,2020,10.1111/apt.16147,https://experts.mcmaster.ca/display/publication1702655,2025-07-27T15:11:22.867217
Neeraj Narula,narulan@mcmaster.ca,conferences,WEEK 2 ADALIMUMAB LEVEL PREDICTS SHORT-TERM CLINICAL REMISSION IN PATIENTS WITH IBD,Gastroenterology,2019,,https://experts.mcmaster.ca/display/publication1644835,2025-07-27T15:11:22.867218
Neeraj Narula,narulan@mcmaster.ca,conferences,Mode of delivery and risk of inflammatory bowel disease,Journal of Crohn's and Colitis,2019,,https://experts.mcmaster.ca/display/publication1634546,2025-07-27T15:11:22.867219
Neeraj Narula,narulan@mcmaster.ca,conferences,Surveillance colonoscopies in ulcerative colitis: does it make a difference?,Journal of Crohn's and Colitis,2019,,https://experts.mcmaster.ca/display/publication1634547,2025-07-27T15:11:22.867220
Neeraj Narula,narulan@mcmaster.ca,conferences,P607 Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease,Journal of Crohn's and Colitis,2019,10.1093/ecco-jcc/jjy222.731,https://experts.mcmaster.ca/display/publication1634545,2025-07-27T15:11:22.867221
Neeraj Narula,narulan@mcmaster.ca,conferences,Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn's disease patients who have failed infliximab,Journal of Crohn's and Colitis,2018,,https://experts.mcmaster.ca/display/publication1518038,2025-07-27T15:11:22.867222
Neeraj Narula,narulan@mcmaster.ca,conferences,Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis,Journal of Crohn's and Colitis,2018,,https://experts.mcmaster.ca/display/publication1518039,2025-07-27T15:11:22.867223
Neeraj Narula,narulan@mcmaster.ca,conferences,Systematic review and meta-analysis: Patient-reported outcomes and endoscopic appearance in ulcerative colitis,Journal of Crohn's and Colitis,2018,,https://experts.mcmaster.ca/display/publication1515487,2025-07-27T15:11:22.867224
Neeraj Narula,narulan@mcmaster.ca,conferences,Higher Adalimumab Maintenance Regimens Are More Effective Than Standard Maintenance Regimens in Crohnʼs Disease Patients Who Have Failed Infliximab,American Journal of Gastroenterology,2017,10.14309/00000434-201710001-00745,https://experts.mcmaster.ca/display/publication1581199,2025-07-27T15:11:22.867225
Neeraj Narula,narulan@mcmaster.ca,conferences,Systematic review with meta‐analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease,Alimentary Pharmacology and Therapeutics,2017,10.1111/apt.14253,https://experts.mcmaster.ca/display/publication1080333,2025-07-27T15:11:22.867226
Neeraj Narula,narulan@mcmaster.ca,conferences,"Persistent Symptoms, CRP Elevation and Treatment Changes Over Time in Crohn's Disease Patients are Associated with Bowel Damage Progression as Expressed by Deterioration of Lemann Index Score",Gastroenterology,2017,10.1016/s0016-5085(17)32719-1,https://experts.mcmaster.ca/display/publication1333703,2025-07-27T15:11:22.867227
Neeraj Narula,narulan@mcmaster.ca,conferences,Proximal Disease Extension in Limited Ulcerative Colitis: A Systematic Review and Meta-Analysis,Gastroenterology,2017,10.1016/s0016-5085(17)33309-7,https://experts.mcmaster.ca/display/publication1333708,2025-07-27T15:11:22.867228
Neeraj Narula,narulan@mcmaster.ca,conferences,Ulcerative Colitis Patients on Vedolizumab Lacking Response at Induction Phase Continue to Improve Over the First 6 Months of Treatment,Gastroenterology,2017,10.1016/s0016-5085(17)31575-5,https://experts.mcmaster.ca/display/publication1333709,2025-07-27T15:11:22.867229
Neeraj Narula,narulan@mcmaster.ca,conferences,C-reactive protein improvement after vedolizumab induction phase is associated with remission after 6 months of treatment in ulcerative colitis patients,Journal of Crohn's and Colitis,2017,,https://experts.mcmaster.ca/display/publication1333745,2025-07-27T15:11:22.867230
Neeraj Narula,narulan@mcmaster.ca,conferences,Impact of adalimumab's patient support program on clinical outcomes in inflammatory bowel diseases: results from the COMPANION study,Journal of Crohn's and Colitis,2017,,https://experts.mcmaster.ca/display/publication485172,2025-07-27T15:11:22.867231
Neeraj Narula,narulan@mcmaster.ca,conferences,"Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration of Lemann Index score",Journal of Crohn's and Colitis,2017,,https://experts.mcmaster.ca/display/publication1333736,2025-07-27T15:11:22.867232
Neeraj Narula,narulan@mcmaster.ca,conferences,Proximal Disease Extension in Limited Ulcerative Colitis: A Systematic Review and Meta-Analysis,Inflammatory Bowel Diseases,2017,,https://experts.mcmaster.ca/display/publication1333734,2025-07-27T15:11:22.867284
Neeraj Narula,narulan@mcmaster.ca,conferences,Proximal disease extension in limited ulcerative colitis: a systematic review and meta-analysis,Journal of Crohn's and Colitis,2017,,https://experts.mcmaster.ca/display/publication1333742,2025-07-27T15:11:22.867285
Neeraj Narula,narulan@mcmaster.ca,conferences,Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011,Journal of Crohn's and Colitis,2017,,https://experts.mcmaster.ca/display/publication1333733,2025-07-27T15:11:22.867286
Neeraj Narula,narulan@mcmaster.ca,conferences,Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment,Journal of Crohn's and Colitis,2017,,https://experts.mcmaster.ca/display/publication1333738,2025-07-27T15:11:22.867287
Neeraj Narula,narulan@mcmaster.ca,conferences,PUB006 Impact of the New WHO Classification of Thymic Tumors: Cross-Validation of the Prognostic Value in a Single Institution Cohort,Journal of Thoracic Oncology,2017,10.1016/j.jtho.2016.11.1976,https://experts.mcmaster.ca/display/publication1484036,2025-07-27T15:11:22.867288
Neeraj Narula,narulan@mcmaster.ca,conferences,Prognostic Value of the New WHO Thymoma Classification: Single institution Cross Validation Study,Journal of Thoracic Oncology,2016,10.1016/j.jtho.2016.09.061,https://experts.mcmaster.ca/display/publication1511865,2025-07-27T15:11:22.867289
Neeraj Narula,narulan@mcmaster.ca,conferences,Outcomes of Second- and Third-LineTumor Necrosis Factor-Î± Antagonists in Inflammatory Bowel Disease,American Journal of Gastroenterology,2016,10.14309/00000434-201610001-00985,https://experts.mcmaster.ca/display/publication1333728,2025-07-27T15:11:22.867290
Neeraj Narula,narulan@mcmaster.ca,conferences,Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy,Arthritis & Rheumatology,2016,,https://experts.mcmaster.ca/display/publication1489861,2025-07-27T15:11:22.867291
Neeraj Narula,narulan@mcmaster.ca,conferences,Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice,Gastroenterology,2016,10.1016/s0016-5085(16)31377-4,https://experts.mcmaster.ca/display/publication1320061,2025-07-27T15:11:22.867292
Neeraj Narula,narulan@mcmaster.ca,conferences,Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice,Gastroenterology,2016,10.1016/s0016-5085(16)31378-6,https://experts.mcmaster.ca/display/publication1320068,2025-07-27T15:11:22.867293
Neeraj Narula,narulan@mcmaster.ca,conferences,Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium,Gastroenterology,2016,10.1016/s0016-5085(16)33301-7,https://experts.mcmaster.ca/display/publication1320067,2025-07-27T15:11:22.867294
Neeraj Narula,narulan@mcmaster.ca,conferences,Impact of high-dose vitamin D3 supplementation in treatment of Crohn's disease in remission: a randomised double-blind controlled study,Journal of Crohn's and Colitis,2016,,https://experts.mcmaster.ca/display/publication1333746,2025-07-27T15:11:22.867295
Neeraj Narula,narulan@mcmaster.ca,conferences,Mucosal Healing Is Associated with Improved Long-Term Outcomes in Crohn's Disease: A Systematic Review and Meta-analysis,Inflammatory Bowel Diseases,2016,,https://experts.mcmaster.ca/display/publication1333731,2025-07-27T15:11:22.867296
Neeraj Narula,narulan@mcmaster.ca,conferences,Mucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis,Inflammatory Bowel Diseases,2016,,https://experts.mcmaster.ca/display/publication1333724,2025-07-27T15:11:22.867297
Neeraj Narula,narulan@mcmaster.ca,conferences,P-064 Impact of High Dose Vitamin D3 Supplementation in Treatment of Crohnʼs Disease in Remission,Inflammatory Bowel Diseases,2016,10.1097/01.mib.0000480168.31416.a6,https://experts.mcmaster.ca/display/publication1333735,2025-07-27T15:11:22.867298
Neeraj Narula,narulan@mcmaster.ca,conferences,Mucosal Healing Is Associated With Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis Presidential Poster,American Journal of Gastroenterology,2015,10.14309/00000434-201510001-01953,https://experts.mcmaster.ca/display/publication1333748,2025-07-27T15:11:22.867299
Neeraj Narula,narulan@mcmaster.ca,conferences,Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium,American Journal of Gastroenterology,2015,10.14309/00000434-201510001-01904,https://experts.mcmaster.ca/display/publication1333760,2025-07-27T15:11:22.867300
Neeraj Narula,narulan@mcmaster.ca,conferences,Systematic Review and Meta-Analysis: Infliximab or Ciclosporin as Rescue Therapy in Patients with Severe Ulcerative Colitis Refractory to Steroids,Journal of Crohn's and Colitis,2015,,https://experts.mcmaster.ca/display/publication932574,2025-07-27T15:11:22.867301
Neeraj Narula,narulan@mcmaster.ca,conferences,Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids: A Systematic Review and Meta-Analysis,American Journal of Gastroenterology,2014,10.14309/00000434-201410002-01772,https://experts.mcmaster.ca/display/publication932568,2025-07-27T15:11:22.867302
Neeraj Narula,narulan@mcmaster.ca,conferences,Anti-TNF alpha Therapies Are Safe During Pregnancy in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis,Gastroenterology,2014,,https://experts.mcmaster.ca/display/publication485182,2025-07-27T15:11:22.867303
Neeraj Narula,narulan@mcmaster.ca,conferences,DOP040 Anti-TNF-α therapies are safe during pregnancy in patients with inflammatory bowel disease: a meta-analysis,Journal of Crohn's and Colitis,2014,10.1016/s1873-9946(14)60065-9,https://experts.mcmaster.ca/display/publication1333751,2025-07-27T15:11:22.867304
Neeraj Narula,narulan@mcmaster.ca,conferences,An Audit of Fecal Occult Blood Testing in Hospital Inpatients,American Journal of Gastroenterology,2013,10.14309/00000434-201310001-01650,https://experts.mcmaster.ca/display/publication610307,2025-07-27T15:11:22.867305
Neeraj Narula,narulan@mcmaster.ca,conferences,Peri-operative Anti-TNFα Treatment and Post-operative Complications in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis,American Journal of Gastroenterology,2013,10.14309/00000434-201310001-01824,https://experts.mcmaster.ca/display/publication1333777,2025-07-27T15:11:22.867306
Neeraj Narula,narulan@mcmaster.ca,other,Interim Analysis of a Trial Evaluating the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Inflammatory Bowel Disease,Clinical Gastroenterology and Hepatology,2024,10.1016/j.cgh.2023.12.007,https://experts.mcmaster.ca/display/publication3445727,2025-07-27T15:11:22.867307
